Natasha Kekre profile picture

Contact Information

Natasha Kekre, BSc, MD, MPH, FRCPC
6137378899 x.71064

501 Smyth Road
CPCR Box 201A
Ottawa, ON
K1H 8L6

ORCID logo

Natasha Kekre

Associate Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Hematologist, Blood and Marrow Transplant Program
The Ottawa Hospital
Assistant Professor
University of Ottawa

Research Interests

Hematopoietic Stem Cell Transplantation
Oncolytic Viruses
Cellular immunotherapy (CAR-T cells)
Clinical Epidemiology 

Brief Biography

Dr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology, within the Blood and Marrow Transplant Program at The Ottawa Hospital, effective October 2015. She is also an associate scientist within the Ottawa Hospital Research Institute and an assistant professor of medicine at the University of Ottawa. She completed her Bachelor’s in Science at the University of Windsor then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in Internal Medicine and Hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston, MA with a Masters in Public Health from Harvard University.

Her research is focused on developing early phase clinical trials and moving home grown therapeutic strategies into patients. She collaborates with a number of local investigators and scientists in Ottawa, studying hematologic malignancies and blood and marrow transplant recipients more specifically. Her laboratory research focuses on oncolytic virus infected cell vaccine therapy in leukemia.  She is also collaborating with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells), bringing this exciting new therapy to Canadian patients. Her other clinical research interests include improving transplant related outcomes and projects with an epidemiologic focus, including but not limited to decision modeling and meta-analyses.

She also participates with a number of cooperative groups in North America including the Center for International Blood and Marrow Transplant Research, the Canadian Blood and Marrow Transplant Group, the American Society of Hematology and the American Society for Blood and Marrow Transplantation.

Selected Publications

1: Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Corral LL, Solano C, Armand P, Perez-Simon JA. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients undergoing Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2016 Jul 25. pii: S1083-8791(16)30222-1. doi: 10.1016/j.bbmt.2016.07.006.

2: Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014 Jul 17;124(3):334-43.

3: Kekre N, Mak KS, Stopsack KH, Binder M, Ishii K, Brånvall E, Cutler CS. Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. Am J Hematol. 2016 Jun;91(6):551-5.

4: Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep;100(9):1222-7.

5: Kekre N, Tokessy M, Mallick R, McDiarmid S, Huebsch L, Bredeson C, Allan D, Tay J, Tinmouth A, Sheppard D. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal  leukoreduction? Biol Blood Marrow Transplant. 2013 Dec;19(12):1719-24.

Diseases, conditions and populations of interest

Research and clinical approaches